Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines

This article was originally published in The Pink Sheet Daily

Executive Summary

A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.

You may also be interested in...



European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation

German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.

Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy

Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.

ScanCell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma

ScanCell Holdings’ potential DNA cancer vaccine, which is administered via an electrical field-driven device, shows preliminary evidence of efficacy in late-stage melanoma patients.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS076064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel